8,868 followers
RT @LizHoffmanbmc: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis h…
RT @LizHoffmanbmc: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis h…
Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis https://t.co/lyA2UlievA https://t.co/ULMU3p3Dgq